DE60038624D1 - Methoden zur behandlung von festen tumoren und metastasen mit gentherapie - Google Patents
Methoden zur behandlung von festen tumoren und metastasen mit gentherapieInfo
- Publication number
- DE60038624D1 DE60038624D1 DE60038624T DE60038624T DE60038624D1 DE 60038624 D1 DE60038624 D1 DE 60038624D1 DE 60038624 T DE60038624 T DE 60038624T DE 60038624 T DE60038624 T DE 60038624T DE 60038624 D1 DE60038624 D1 DE 60038624D1
- Authority
- DE
- Germany
- Prior art keywords
- gene therapy
- metastases
- methods
- solid tumors
- treating solid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15806899P | 1999-10-07 | 1999-10-07 | |
US158068P | 1999-10-07 | ||
PCT/US2000/027547 WO2001024684A2 (en) | 1999-10-07 | 2000-10-07 | Methods for treatment of solid tumors and metastasis by gene therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60038624D1 true DE60038624D1 (de) | 2008-05-29 |
DE60038624T2 DE60038624T2 (de) | 2009-06-10 |
Family
ID=22566564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60038624T Expired - Lifetime DE60038624T2 (de) | 1999-10-07 | 2000-10-07 | Methoden zur behandlung von festen tumoren und metastasen mit gentherapie |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1223952B1 (de) |
JP (2) | JP5557974B2 (de) |
AT (1) | ATE392210T1 (de) |
AU (1) | AU7862600A (de) |
CA (1) | CA2386374A1 (de) |
DE (1) | DE60038624T2 (de) |
WO (1) | WO2001024684A2 (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030086903A1 (en) | 2001-11-02 | 2003-05-08 | Genvec, Inc. | Therapeutic regimen for treating cancer |
WO2003088954A1 (en) * | 2002-04-15 | 2003-10-30 | Sloan-Kettering Institute For Cancer Research | Combination therapy for the treatment of cancer |
JP2005535676A (ja) * | 2002-07-19 | 2005-11-24 | ラドウィッグ・インスティテュート・フォー・キャンサー・リサーチ | 腫瘍の処置における放射免疫療法の効果の増強 |
EP1687032B1 (de) | 2003-11-14 | 2010-02-24 | Genvec, Inc. | Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc). |
JP4560629B2 (ja) * | 2005-03-31 | 2010-10-13 | 国立大学法人 筑波大学 | 腫瘍壊死誘導療法の抗腫瘍効果増強剤 |
JP6130391B2 (ja) | 2011-11-23 | 2017-05-17 | インテリカイン, エルエルシー | Mtor阻害剤を使用する強化された治療レジメン |
EP3268362B1 (de) | 2015-03-11 | 2021-10-20 | Peloton Therapeutics, Inc. | Substituierte pyridine und verwendungen davon |
CA3002381A1 (en) | 2015-10-21 | 2017-04-27 | Teclison Limited | Compositions and methods for immune-mediated cancer therapy |
EP3205356A1 (de) * | 2016-02-10 | 2017-08-16 | Onkoloski Institut Ljubljana | Plasmidexpressionsvektor zur codierung von humanem interleukin 12 unter transkriptionskontrolle von p21-promotor und ohne antibiotikaresistenz für krebsgentherapie und andere verwendungen davon |
EP3810109A4 (de) | 2018-05-31 | 2022-03-16 | Peloton Therapeutics, Inc. | Zusammensetzungen und verfahren zur hemmung von cd73 |
SG11202104208RA (en) | 2018-10-30 | 2021-05-28 | Peloton Therapeutics Inc | Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof |
JP2023526332A (ja) | 2020-05-15 | 2023-06-21 | アルゲン バイオテクノロジーズ,インク. | 特定の化学組成物およびその使用方法 |
BR112022025512A2 (pt) * | 2020-06-15 | 2023-01-17 | Kortuc Inc | Sensibilizador para tratamento de câncer |
KR102570785B1 (ko) * | 2021-05-06 | 2023-08-24 | 연세대학교 산학협력단 | 화학방사선요법에 대한 정보 제공 방법 및 이를 적용한 디바이스 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5747469A (en) * | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
JPH06509578A (ja) * | 1991-07-26 | 1994-10-27 | ユニバーシティ・オブ・ロチェスター | 悪性細胞利用による癌治療法 |
US5952221A (en) * | 1996-03-06 | 1999-09-14 | Avigen, Inc. | Adeno-associated virus vectors comprising a first and second nucleic acid sequence |
EP0973926A1 (de) * | 1997-03-14 | 2000-01-26 | Selective Genetics, Inc. | Adenovirale vektoren mit verändertem tropismus |
WO1999038992A1 (en) * | 1998-02-03 | 1999-08-05 | Baylor College Of Medicine | Synergism between thymidine kinase gene therapy and topoisomerase i and topoisomerase ii inhibitors |
-
2000
- 2000-10-07 AT AT00968760T patent/ATE392210T1/de not_active IP Right Cessation
- 2000-10-07 JP JP2001527689A patent/JP5557974B2/ja not_active Expired - Fee Related
- 2000-10-07 WO PCT/US2000/027547 patent/WO2001024684A2/en active Search and Examination
- 2000-10-07 AU AU78626/00A patent/AU7862600A/en not_active Abandoned
- 2000-10-07 CA CA002386374A patent/CA2386374A1/en not_active Abandoned
- 2000-10-07 EP EP00968760A patent/EP1223952B1/de not_active Expired - Lifetime
- 2000-10-07 DE DE60038624T patent/DE60038624T2/de not_active Expired - Lifetime
-
2011
- 2011-10-03 JP JP2011219632A patent/JP2012001566A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2012001566A (ja) | 2012-01-05 |
WO2001024684A3 (en) | 2001-10-25 |
JP2003528813A (ja) | 2003-09-30 |
CA2386374A1 (en) | 2001-04-12 |
ATE392210T1 (de) | 2008-05-15 |
WO2001024684A2 (en) | 2001-04-12 |
JP5557974B2 (ja) | 2014-07-23 |
AU7862600A (en) | 2001-05-10 |
EP1223952A4 (de) | 2004-12-08 |
EP1223952A2 (de) | 2002-07-24 |
EP1223952B1 (de) | 2008-04-16 |
DE60038624T2 (de) | 2009-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60038624D1 (de) | Methoden zur behandlung von festen tumoren und metastasen mit gentherapie | |
MX342777B (es) | Inhibidores tnfa para usarse en el tratamiento de trastornos relacionados con tnfa. | |
IL178042A0 (en) | Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation | |
TR200003879T2 (tr) | İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@ | |
TW200728465A (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
MXPA03000527A (es) | Composiciones y metodos para la terapia y diagnostico de cancer ovarico. | |
WO2002066044A3 (en) | Method for dendritic cells based immunotherapy of tumors using combination therapy | |
RU2014121335A (ru) | Иммуногенное лечение рака | |
EP0719150A4 (de) | Zellulärer impfstoff und verwendungsmethoden für die behandlung von malignen, soliden tumoren | |
WO1999051263A3 (en) | Methods and modified cells for the treatment of cancer | |
EA202192757A1 (ru) | Способ лечения опухолей | |
ATE313334T1 (de) | Behandlung von tumoren mit photodynamischer therapie | |
NO20002412L (no) | FremgangsmÕte for behandling av tumorer og tumorceller ved anvendelse av ex vivo aktiverte T celler | |
UA88294C2 (ru) | ПРИМЕНЕНИЕ АНТИ-α5β1 АНТИТЕЛ ДЛЯ УГНЕТЕНИЯ ПРОЛИФЕРАЦИИ РАКОВЫХ КЛЕТОК | |
MX2023010825A (es) | Metodos para tratar el cancer con anticuerpos anti-ilt3. | |
DE60212415D1 (de) | Die verwendung von einer 4-pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren | |
ATE383154T1 (de) | Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivaten und radiotherapie | |
FitzGerald et al. | Prostate carcinoma: opportunities for translational research | |
AU2003229876A1 (en) | Tumour associated antigens | |
MX2021015802A (es) | Terapia de combinacion. | |
MXPA05002477A (es) | Asialo-interferones y el tratamiento de cancer de higado. | |
WO2001028573A3 (en) | Monocyte conditioned medium for cancer treatment | |
MD2378F1 (en) | Method of determining the parameters for cryoapplication | |
CY1116323T1 (el) | ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ TNFα-ΣΧΕΤΙΖΟΜΕΝΩΝ ΔΙΑΤΑΡΑΧΩΝ | |
UA40084A (uk) | Спосіб лікування занедбаних форм раку молочної залози без наявності віддалених метастазів |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |